Skip to main content

Advertisement

Table 1 Sample Characteristics

From: A pilot open series of lamotrigine in DBT-treated eating disorders characterized by significant affective dysregulation and poor impulse control

ID Age Ethnicity Race BMI (kg/m2) Diagnosis at Admission Days on Lamotrigine at Baseline Assessment Total Days on Lamotrigine Final Lamotrigine Dose (mg/day) Concurrent Medications
1 28 Non-Hispanic Black 26.3 EDNOSa −2 223 150 quetiapine XR, bupropion XL, levomilnacipran
2 23 Non-Hispanic White 20.2 EDNOSb −5 246 200 duloxetine, trazodone
3 41 Non-Hispanic White 21.9 EDNOSc −4 253 100 escitalopram
4 42 Hispanic Other 28.3 BN 1 190 100 venlafaxine XR, naltrexone
5 18 Non-Hispanic White 19.7 AN-BP 1 86 200 sertraline, gabapentin
6 31 Non-Hispanic White 20.1 AN-BP 1 85 200 gabapentin, naltrexone
7 25 Non-Hispanic White 19.1 AN-R 0 102 200 duloxetine, sertralined
8 31 Hispanic Other 22.3 AN-BP 0 71 100 fluoxetine
9 32 Non-Hispanic Other 25.7 BN 1 71 200 duloxetine
  1. aHigh-normal to mildly overweight with restrictive eating and purging; bMildly underweight AN with alternating severe restrictive eating, bingeing, and occasional purging; cLifetime history of mostly BN with episodes of AN-BP. During period of study, most characteristic of low-normal-weight AN-P; dDuloxetine was concurrent with lamotrigine for one month and was subsequently replaced with sertraline in the second month. In the third month, lamotrigine was the only medication prescribed. BMI = body mass index; AN-BP = anorexia nervosa, binge-eating/purging subtype; EDNOS = eating disorder not otherwise specified; BN = bulimia nervosa